IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…
IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On ...
Clinical Trials Arena6d
FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment
Imunon has announced the alignment of the FDA with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol.
CURE6d
Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...
Imunon, Inc.: IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivo ...
Imunon finalizes Phase 3 study design with FDA for IMNN-001
IMUNON (IMNN) announced that the U.S. Food and Drug Administration is aligned with the protocol for the Phase 3 pivotal trial, called OVATION ...
Admiral Markets16d
Imunon Inc
The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include ...
Yahoo Finance20d
Imunon, Inc. (IMNN)
IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in Q1 ...